High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome

References

• Galluzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis 2008;18:511–518.
   PubMed Web of Science ®Google Scholar
• Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141–154.
   PubMed Web of Science ®Google Scholar
• Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm 2010;2010:758656.
   PubMed Web of Science ®Google Scholar
• Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89:2160–2165.
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. Inflammation and insulin resistance. Diabetes Care 2003;26:1922–1926.
   PubMed Web of Science ®Google Scholar
• Andersson CX, Gustafson B, Hammarstedt A, Hedjazifar S, Smith U. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab Res Rev 2008;24:595–603.
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, Spreafico F, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997;272:32817–32823.
   PubMed Web of Science ®Google Scholar
• Lee DH, Jeon HK, You JH, Park MY, Lee SJ, Kim SS, Shim BJ, et al. Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome. Korean Circ J 2010;40:370–376.
   PubMedGoogle Scholar
• Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337–366.
   PubMed Web of Science ®Google Scholar
• Alberti L, Gilardini L, Zulian A, Micheletto G, Peri G, Doni A, Mantovani A, Invitti C. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis 2009;202:455–460.
   PubMed Web of Science ®Google Scholar
• Salustri A, Garlanda C, Hirsch E, De Acetis M, Maccagno A, Bottazzi B, Doni A, et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 2004;131:1577–1586.
   PubMed Web of Science ®Google Scholar
• Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM, Yenicesu M, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008;3:976–985.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19–25.
   Web of Science ®Google Scholar
• Cho LW, Randeva HS, Atkin SL. Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag 2007;3:55–63.
   PubMedGoogle Scholar
• Kirschner MA, Samojlik E, Drejka M, Szmal E, Schneider G, Ertel N. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 1990;70:473–479.
   PubMed Web of Science ®Google Scholar
• Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414–2421.
   PubMed Web of Science ®Google Scholar
• Hu W, Qiao J, Yang Y, Wang L, Li R. Elevated C-reactive protein and monocyte chemoattractant protein-1 in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011;157:53–56.
   PubMed Web of Science ®Google Scholar
• González F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metab Clin Exp 2009;58:954–962.
   PubMed Web of Science ®Google Scholar
• Sayin NC, Gücer F, Balkanli-Kaplan P, Yüce MA, Ciftci S, Kücük M, Yardim T. Elevated serum TNF-α levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med 2003;48:165–170.
   PubMed Web of Science ®Google Scholar
• Kolbus A, Walch K, Nagele F, Wenzl R, Unfried G, Huber JC. Interleukin-1 α but not interleukin-1 β gene polymorphism is associated with polycystic ovary syndrome. J Reprod Immunol 2007;73:188–193.
   PubMed Web of Science ®Google Scholar
• Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237–242.
   PubMed Web of Science ®Google Scholar
• Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994;15:81–88.
   PubMedGoogle Scholar
• Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, Emura I, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008;215:48–55.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, Sagara M, Kubota I. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75–81.
   PubMed Web of Science ®Google Scholar
• Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636–641.
   PubMed Web of Science ®Google Scholar
• Kotooka N, Inoue T, Aoki S, Anan M, Komoda H, Node K. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008;130:19–22.
   PubMed Web of Science ®Google Scholar
• Liu S, Navarro G, Mauvais-Jarvis F. Androgen excess produces systemic oxidative stress and predisposes to β-cell failure in female mice. PLoS One 2010;5: e11302.
   Web of Science ®Google Scholar
• Holmäng A, Svedberg J, Jennische E, Björntorp P. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 1990;259:E555–E560.
   PubMedGoogle Scholar
• O’Meara NM, Blackman JD, Ehrmann DA, Barnes RB, Jaspan JB, Rosenfield RL, Polonsky KS. Defects in β-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993;76:1241–1247.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Finegood DT. β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942–947.
   PubMed Web of Science ®Google Scholar